

REVIEW ARTICLE

Open Access



Lasmiditan mechanism of action – review of a selective 5-HT_{1F} agonist

David B. Clemow^{1*}, Kirk W. Johnson¹, Helen M. Hochstetler¹, Michael H. Ossipov², Ann M. Hake^{1,3} and Andrew M. Blumenfeld⁴

Abstract

Migraine is a leading cause of disability worldwide, but it is still underdiagnosed and undertreated. Research on the pathophysiology of this neurological disease led to the discovery that calcitonin gene-related peptide (CGRP) is a key neuropeptide involved in pain signaling during a migraine attack. CGRP-mediated neuronal sensitization and glutamate-based second- and third-order neuronal signaling may be an important component involved in migraine pain. The activation of several serotonergic receptor subtypes can block the release of CGRP, other neuropeptides, and neurotransmitters, and can relieve the symptoms of migraine. Triptans were the first therapeutics developed for the treatment of migraine, working through serotonin 5-HT_{1B/1D} receptors. The discovery that the serotonin 1F (5-HT_{1F}) receptor was expressed in the human trigeminal ganglion suggested that this receptor subtype may have a role in the treatment of migraine. The 5-HT_{1F} receptor is found on terminals and cell bodies of trigeminal ganglion neurons and can modulate the release of CGRP from these nerves. Unlike 5-HT_{1B} receptors, the activation of 5-HT_{1F} receptors does not cause vasoconstriction.

The potency of different serotonergic agonists towards 5-HT_{1F} was correlated in an animal model of migraine (dural plasma protein extravasation model) leading to the development of lasmiditan. Lasmiditan is a newly approved acute treatment for migraine in the United States and is a lipophilic, highly selective 5-HT_{1F} agonist that can cross the blood-brain barrier and act at peripheral nervous system (PNS) and central nervous system (CNS) sites.

Lasmiditan activation of CNS-located 5-HT_{1F} receptors (e.g., in the trigeminal nucleus caudalis) could potentially block the release of CGRP and the neurotransmitter glutamate, thus preventing and possibly reversing the development of central sensitization. Activation of 5-HT_{1F} receptors in the thalamus can block secondary central sensitization of this region, which is associated with progression of migraine and extracephalic cutaneous allodynia. The 5-HT_{1F} receptors are also elements of descending pain modulation, presenting another site where lasmiditan may alleviate migraine. There is emerging evidence that mitochondrial dysfunction might be implicated in the pathophysiology of migraine, and that 5-HT_{1F} receptors can promote mitochondrial biogenesis. While the exact mechanism is unknown, evidence suggests that lasmiditan can alleviate migraine through 5-HT_{1F} agonist activity that leads to inhibition of neuropeptide and neurotransmitter release and inhibition of PNS trigeminovascular and CNS pain signaling pathways.

Keywords: Migraine, Lasmiditan, Lipophilicity, Brain penetration, 5-HT_{1F}, CGRP, Glutamate

* Correspondence: davidclemow@lilly.com

¹Eli Lilly and Company, Indianapolis, IN, USA

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Migraine is a painful, disabling neurological disease that has long afflicted the population worldwide. It was only in the past few decades that inroads have been made into understanding the pathophysiology of migraine and that specific treatments for migraine were developed [1]. The vascular theory of migraine held that the disorder was caused by vasodilation of meningeal arteries [1]. Based on this prevailing viewpoint, the prototypic triptan, sumatriptan, was initially developed to treat migraine due to its vasoconstrictive properties. The clinical success of sumatriptan led to the introduction of second-generation triptans and spurred an increased research effort into understanding the pathophysiology of migraine.

Numerous studies have since provided convincing evidence that migraine is a neurological disease with a prominent role in the activation of the trigeminovascular system (Fig. 1a, [Supplemental Video](#)). It was also determined that calcitonin gene-related peptide (CGRP), a neuropeptide prominently expressed in trigeminal afferent neurons, plays a key role in the neurophysiology of migraine (Fig. 2a, [Supplemental Video](#)) [2–4]. Research has shown that the triptans exert their antimigraine effects by blocking the release of CGRP and potentially other neuropeptides from trigeminal afferent fibers. The triptans appear to work through activation of the serotonergic 5-HT_{1B/D} receptors rather than vasoconstriction [2, 3, 5]. The vasoconstrictive effect is mediated through the 5-HT_{1B} receptor [5].

Triptans are generally considered safe overall, but they are contraindicated in patients with uncontrolled hypertension and other cardiovascular and cerebrovascular diseases [6]. The triptans vary somewhat in their ability to cross the blood-brain barrier (BBB). Data suggests that overall, the triptans seem to remain largely restricted to peripheral nervous system (PNS) sites of action [6]. However, recent evidence in rats suggests that subcutaneous sumatriptan can accumulate rapidly in the central nervous system (CNS) [7, 8]. The development and clinical efficacy of non-vasoconstriction drugs for the treatment of migraine led to the conclusion and current predominate theory that vasoconstriction is not the triptan's therapeutic mechanism of action. Attempts to develop 5-HT_{1D} agonists to treat migraine were largely unsuccessful; and a newly recognized class of drugs, the “ditans,” was developed to selectively act at the 5-HT_{1F} receptor.

With its approval in October 2019 in the United States, lasmiditan is currently the only selective 5-HT_{1F} agonist approved for treatment of acute migraine attack. Lasmiditan is considered a first-in-class “ditan” based upon its unique chemical structure with a pyridinoylpiperidine scaffold structure, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl] benzamide

hemisuccinate, and its selective high affinity for the 5-HT_{1F} receptor. Preclinical studies showed that lasmiditan is devoid of vasoconstrictive effects [9] and that it penetrates the BBB into the CNS [10], which is important since the CNS also plays a role in the management of migraine [11]. Lasmiditan has shown efficacy in the acute treatment of migraine in randomized, double-blind, placebo-controlled clinical trials (RCT) [12–15]. This narrative review highlights the pharmacology and pharmacokinetics of lasmiditan and its pharmacological activity at the 5-HT_{1F} receptor as well as the role of the 5-HT_{1F} receptor as a potential mechanism to be exploited in treating migraine.

This review discusses the potential mechanism of action for lasmiditan in the context of overall migraine pathophysiology. Data supports that migraine pathophysiology involves activation of the hypothalamus, producing the prodrome phase premonitory symptoms of migraine that are followed by trigeminal ganglion (TG) activation, which leads to the headache phase [16]. Trigeminal system activation results in the release of multiple neuropeptides, including CGRP, pituitary adenylate cyclase-activating polypeptide (PACAP), and substance P, at both the PNS and CNS terminals of the trigeminal nerve [17]. CGRP has been shown to be involved in migraine [2]. Preclinical and clinical studies failed to support a role for substance P in migraine. Although substance P and CGRP are co-localized in pre-synaptic vesicles and released together [18], trials assessing agents that block only substance P have not shown benefit in the treatment of migraine [19, 20]. Conversely, emerging evidence suggests that PACAP may contribute to migraine [17, 21].

Afferent activation of the trigemino-thalamic pathway and sensory cortex leads to sensitization and allodynia, which can lead to chronification – progression in frequency of migraine attacks [16, 22]. The CNS afferent pathways involve the excitatory neurotransmitter glutamate. The ascending CNS pain pathways are modulated by descending pain modulatory pathways that include projections to the periaqueductal gray matter (PAG), noradrenergic locus coeruleus, and the nucleus raphe magnus (NRM). The descending pathways relay serotonergic and non-serotonergic pain inhibitory and facilitatory neural projections [23–27]. Inhibitory projections can attenuate pain signaling likely in part by activating 5-HT_{1F} receptors on glutamate-containing neurons [3, 24]. These anatomic and neuronal signaling pathways could be potential neurological points of activity for ditan therapy.

Literature search methods

The PubMed, Embase, and Cochrane Library databases were searched for the terms “LY573144, lasmiditan, OR




Fig. 1 **a** Trigeminal and pain pathways associated with pain signaling during a migraine attack plus 5-HT_{1F} receptor locations in PNS and CNS areas involved in the pathophysiology of migraine. **b** Activation of trigeminal and pain pathways during a migraine attack; sustained or repeated activation of pain pathways leads to increasing sensitivity of trigeminal neurons in the brain stem. **c** Activated nerves release various substances including neuropeptides and neurotransmitters such as CGRP and glutamate that can exacerbate neurogenic inflammation and nociceptor pain signaling in migraine; this may hyperexcite neurons to propagate pain responses and enhance central sensitization. **d** In addition to other endogenous inhibitory processes, serotonin from pain modulating pathways activates 5-HT receptors that can inhibit neuropeptide and neurotransmitter release, thereby inhibiting their local activity and downstream neuronal signaling; however, these modulatory mechanisms may be disturbed in migraine pathophysiology, predisposing patients with migraine to an attack. **e** Lasmiditan crosses the blood-brain barrier and presumably acts in both the PNS and the CNS to selectively activate 5-HT_{1F} receptors to inhibit the release of neuropeptides and neurotransmitters such as CGRP and glutamate, thereby inhibiting their local activity and migraine attack pain pathways. **f** Preclinical and ex vivo human evidence suggests that lasmiditan inhibits PNS trigeminal nerve and CNS pain signaling pathways, exerting therapeutic effects in the treatment of migraine without causing vasoconstriction. Abbreviations: CNS, central nervous system; mRNA, messenger ribonucleic acid; PNS, peripheral nervous system. Note: 5-HT_{1F} receptor locations are based on human and animal mRNA, immunohistochemistry, and functional biology studies




Fig. 2 **a** Neuropeptides and neurotransmitters regulate pain during a migraine attack. Nerve activity in the trigeminovascular pain pathway leads to the release of neuropeptides and neurotransmitters, such as CGRP and glutamate that can hyperexcite neurons, thereby propagating PNS and CNS pain responses. **b** The thalamic trigeminovascular neurons, trigeminal ganglion, and the trigeminal nucleus caudalis are densely innervated with serotonergic neurons. Subtypes of serotonin (5-HT) receptors found in these areas, such as 5-HT_{1F}, are believed to be involved in the pathophysiology of migraine. Serotonin receptor agonists are the foundation of many acute treatments for migraine; however, many of these therapeutics are associated with vasoconstriction through activation of 5-HT_{1B} receptors. Serotonin binding to 5-HT_{1F} receptors can inhibit presynaptic vesicular release of CGRP and inhibit postsynaptic cAMP signaling cascades. Abbreviations: 5-HT, 5-hydroxytryptamine (serotonin); 5-HT₁, 5-hydroxytryptamine 1 receptor; cAMP, cyclic adenosine monophosphate; CGRP, calcitonin gene-related peptide; CNS, central nervous system; PNS, peripheral nervous system

LY334370 OR (COL-144 OR COL144 OR COL 144).” The terms included variations of the “LY” numbers to include hyphens, commas, or spaces, and LY334370 was included since it was a 5-HT_{1F} receptor agonist that preceded lasmiditan in development. A separate search was conducted for “(5-HT OR serotonin) AND (mechanism OR mechanism of action) AND (blood brain barrier) AND (central penetrant) AND (physiology OR pathophysiology OR pharmacology) AND (lasmiditan OR

ditan).” Results were examined to identify primary sources that address the basic pharmacology of 5-HT_{1F} agonists or their potential role in the PNS and CNS in treating migraine. Review articles published in 2018 and 2019 were examined to find any primary sources that may have been missed in the searches. Review articles are included in this manuscript to support ancillary points, to support tangential facts, and to buttress arguments. This is a comprehensive and balanced overview

of the current understanding of the role of 5-HT_{1F} in migraine pathophysiology; therefore, all relevant studies may not be specifically referenced.

PNS and CNS neuropathology of migraine

Research in the mid-1600s proposed that migraine was caused by meningeal vasodilation, a view that persisted through the 1900s [1]. An alternate theory that migraine arose from “nerve storms evolved out of the optic thalamus,” was put forth in 1783 [1]. The current working hypothesis of migraine is that it is a complex neurological disease that is mediated through the trigemino-vascular system (Fig. 1b, [Supplemental Video](#)) [28–30]. Some studies that correlated observations made in animal models with clinical observations, including imaging studies, suggested that the headache phase of a migraine attack corresponds to the development of peripheral sensitization involving the primary afferents from the TG (Fig. 1c, [Supplemental Video](#)) [31–33]. As the attack progresses, central sensitization of the trigeminal nucleus caudalis (TNC) occurs, with enhanced responses of nociceptive TNC neurons, and expansion of receptive fields to facial areas. The TNC has extensive connections with other brain regions. Prolonged activation of the TNC results in sensitization of third-order neurons in the thalamus, which can account for the expansion of cutaneous allodynia to extracephalic regions [31, 33–36]. The TNC also has reciprocal connections with brain regions that are implicated in pain processing, such as the insula, PAG, and the rostral ventromedial medulla [37]. Further progression of central sensitization results in sensitization of thalamic third-order neurons receiving inputs from the TNC; this is associated with the spreading of cutaneous allodynia to extracephalic regions [31, 33]. For example, enhanced activation of the posterior thalamus in response to light cutaneous stimuli applied to the dorsum of the hand of a patient during a migraine attack was demonstrated in one functional magnetic resonance imaging (fMRI) study. The shift from peripheral sensitization to central sensitization may be demonstrated by the coincident loss of efficacy of triptans in reversing a migraine headache as the migraine attack progresses, as many of these therapeutics generally do not appear to act centrally [38].

Recent reviews suggested that the genesis of a migraine attack remains a mystery [24, 25, 39]. It has been proposed that cortical spreading depression (CSD), a wave of depolarization and repolarization across the cortex, may trigger neurogenic inflammation, with plasma extravasation and mast cell degranulation. Previous speculations have associated migraine with disruption of the BBB [40]; however, more recent clinical observations showed that the BBB remains intact during a migraine attack [41, 42]. Animal models were developed to study

these ideas, but it is unclear to what extent they represent the clinical situation. CGRP can degranulate mast cells in rats, but human mast cells do not have functional CGRP receptors and are not responsive to CGRP [43]. Moreover, spontaneous CSD has not been demonstrated in humans, and there are no studies proving that CSD leads to a migraine attack [44].

Imaging studies showed activation of the hypothalamic areas when migraine is provoked by injections of nitroglycerin or CGRP that produce the premonitory symptoms of the prodrome phase before the headache starts. This is consistent with premonitory symptoms such as food craving, fatigue, nausea, and yawning which suggest hypothalamic involvement in migraine [16, 45]. Studies using H₂¹⁵O positron emission tomography (PET) cerebral blood flow scans showed increased hypothalamic activity during the early prodrome phase in patients who had migraine induced with nitroglycerin [46]. Increased hypothalamic activity along with functional coupling to the TNC was detected by fMRI in a patient who experienced two to three migraine attacks per month and underwent daily scans for 30 days [47]. It is believed that oscillations in hypothalamic activity alter functional connections between the hypothalamus and brainstem, altering susceptibility thresholds to sensory stimuli thereby initiating and ending a migraine attack [48]. Another view [24, 45] suggested that cortical excitability influences activity at other sites, including pain modulatory systems, to initiate migraine. A central locus for the initiation of migraine is consistent with the fact that the premonitory symptoms that precede headache can occur many hours before the pain. Peripheral sensitization can develop as a result of enhanced CNS activity through as yet undetermined mechanisms, but possibly involving oscillations in hypothalamic activity, eventually resulting in migraine headache pain [16, 24, 45, 48]. These data point to the importance of the CNS as a potential target tissue for migraine therapy.

Role of CGRP in migraine

During the initial phase of a migraine attack, CGRP is released from trigeminal afferent C-fibers that are bi-directional. This released CGRP can activate the CGRP receptors on adjacent trigeminal afferent A δ fibers that are bi-directional and project back to the TNC (Fig. 2a). While CGRP does not produce nociception, it can promote central sensitization of the TNC second-order neurons. CGRP released in the PNS can dilate the meningeal arteries due to its potent vasodilatory effect, but it also activates signaling cascades that produce nitric oxide (NO) and release glutamate and prostaglandins from the arterial wall. These substances can sensitize and/or activate the trigeminal afferent fibers of the PNS, leading to enhanced release of CGRP and promoting a feed-forward enhancement mechanism.

Activation of these PNS nociceptors is an important step in the early phase of the migraine headache [2, 24, 25].

Continued activation of the primary afferents in the TNC, together with the release of CGRP, as well as glutamate and possibly other neurotransmitters, promotes sensitization of these second-order neurons [49–51]. Central sensitization, driven in large part by the excitatory neurotransmitter glutamate, is associated with reduced activation thresholds, increased firing in response to inputs, continued after-discharge in response to inputs, recruitment of adjacent neurons, and expansion of their fields [31, 33–36, 49, 51]. This mechanism can account for the development of cutaneous allodynia and its expansion in facial regions. Whereas the role of CGRP in the trigeminovascular system is well examined regarding migraine, how or whether CGRP is instrumental at CNS sites requires further investigation.

The small molecule CGRP antagonist, telcagepant, does not appear to act centrally at therapeutic doses [52]. The small molecule GGRP receptor antagonists such as ubrogepant and rimegepant, which were recently approved in the United States for the treatment of migraine attacks [53, 54], appear to predominantly function in the PNS [24, 55]. While the BBB is relatively impermeable to antibodies [56], it is still possible to detect up to approximately 0.1% of the blood concentration in the cerebrospinal fluid [24, 57, 58]; thus, the monoclonal antibodies to CGRP peptide (eptinezumab, fremanezumab, and galcanezumab) could potentially have some level of CNS activity, despite not appearing to penetrate the BBB in large concentrations [24, 57]. These data suggest that there is a need for migraine therapeutics that could act in the CNS. Importantly, the activity of CGRP at CNS sites (e.g., amygdala, PAG, parabrachial nucleus, and NRM) can be either pronociceptive or antinociceptive, depending on the brain region involved, suggesting that the role of CNS CGRP in migraine may be complex [24, 25, 59].

5-HT_{1F} receptor location

The human 5-HT_{1F} receptor was first identified and cloned in 1993 [60]. Messenger RNA (mRNA) for the 5-HT_{1F} receptor was found in human brain, uterine, and mesenteric tissue, but not in heart, kidney, liver, pancreas, spleen, or testes. In situ hybridization showed the presence of mRNA in the cerebral cortex, hippocampus, and dorsal raphe of guinea pig brains [60] and in the guinea pig and human TG [61–63]. In other studies, mRNA for 5-HT_{1F} was detected in human cerebral blood vessels [61], rat meningeal dura mater [64], cerebral cortex, and TG [65]. Moderate levels were detected in coronary and pulmonary blood vessels, but not in skeletal muscles or the mesenteric artery [65]. Studies performed with isolated human microvasculature

detected 5-HT_{1F} message in microvessels and capillaries, but not in cultures of isolated human brain smooth muscle cells, suggesting that the 5-HT_{1F} receptors were present on astrocytes associated with the vessels [66].

Autoradiographic in situ hybridization studies performed with guinea pig brain sections showed the presence of mRNA for 5-HT_{1F} receptors in several regions. These included cortical and hippocampal sites, the claustrum, amygdala, the mediodorsal and laterodorsal thalamic nuclei, supraoptic hypothalamic nucleus, periventricular hypothalamic area, and several midbrain and medullary sites including the dorsal raphe, anterior pretectal area, ventral tegmental nucleus, paragigantocellular reticular nucleus, and the TNC [67].

Prior to the availability of selective ligands for 5-HT_{1F}, triptans were used to visualize the distribution of 5-HT_{1F} receptors as some triptans bind to 5-HT_{1F} in addition to 5-HT_{1B/D}. Autoradiographic studies with [³H]-sumatriptan, with and without 5-carboxamidotryptamin (5-CT) used to displace sumatriptan from 5-HT receptors, showed the presence of the 5-HT_{1D} and 5-HT_{1F} receptor subtypes in the human frontal cortex, globus pallidus, PAG, and TNC [68]. Autoradiography in rats and guinea pigs showed the presence of 5-HT_{1F} in the PAG, TNC, hippocampus, and cortex [69, 70]. Autoradiographic signals in the human brain were observed at high levels in the globus pallidus and substantia nigra, moderate levels in the fronto-temporal cortex, caudate-putamen and hippocampus, and low levels in the cerebellum, pons, medulla, and spinal cord [71].

LY334370 is a high affinity, selective agonist that acts at the 5-HT_{1F} receptor with approximately 300-fold greater selectivity compared to other 5-HT receptors [72] and is a useful pharmacologic tool for examining the 5-HT_{1F} receptor [72]. Thus, [³H]LY334370 was used for autoradiographic studies performed on guinea pig and rat brains, and preliminary studies (*N* = 1 each) with rhesus monkey and human brain sections [72]. In those studies, specific binding sites were detected in the cortex, amygdala, thalamus, nucleus accumbens, caudate putamen, hippocampal CA3 region, olfactory bulb, and tubercle of the rat, as well as in the cortex, caudate putamen, nucleus accumbens, thalamus, and medial mammillary nucleus of the guinea pig [72].

Based on currently described human and animal mRNA, immunohistochemistry, and functional biology studies, 5-HT_{1F} receptor locations are on neuronal synapses within PNS and CNS structures involved in the pathophysiology of migraine and structures modulating associated pain signaling, including but not limited to meninges, TG, trigeminal nucleus caudalis, hypothalamus, thalamus, and cortex (Fig. 1a) [72–76].

Role of 5-HT_{1F} receptor in migraine

Nerve activity in the trigeminovascular pain pathway leads to the release of neuropeptides and neurotransmitters, such as CGRP and glutamate, and this activity is thought to exacerbate neurogenic inflammation and nociceptor pain signaling in migraine (Fig. 1c) [24, 77, 78]. The release of CGRP and glutamate can hyperexcite second-order neurons, which may propagate PNS and CNS pain responses [24, 77, 78]. The 5-HT_{1F} receptors are located on neuronal synapses involved in this modulating of pain signaling (Fig. 2b, Supplemental Video) [74, 75].

Dose-dependent inhibition of forskolin-induced cyclic adenosine monophosphate (cAMP) formation by 5-HT_{1F} agonists showed that the 5-HT_{1F} receptor, like other subtypes in the 5-HT₁ family, is coupled to the G_{i/o} G-protein and, when activated, inhibits adenylate cyclase-mediated formation of cAMP (Fig. 2b). This inhibits the phosphorylation of protein kinase A (PKA) and affects downstream signaling pathways, including the inhibition of neuropeptide and neurotransmitter release [60]. Evidence suggests that serotonin activity at the 5-HT_{1F} receptor on neuronal synapses inhibits the release of CGRP and glutamate, reducing hyperexcitability and regulating pain signaling (Fig. 2b, Fig. 1d, Supplemental Video) [24, 77].

Immunohistochemical studies of cervical, thoracic, and lumbar dorsal root ganglia (DRG) and TG of rats with antibodies selective for 5-HT_{1B}, 5-HT_{1D}, or the 5-HT_{1F} receptors showed that the majority of DRG and TG neurons were labeled for each of the subtypes. Immunolabeling was noted on small-diameter C-fiber neurons, A δ neurons, and the larger A β neurons [73]. Double-labeling immunohistochemistry of TG in rats found that the majority of neurons that were positive for glutamate also expressed the 5-HT_{1B} (64%), 5-HT_{1D} (68%), and the 5-HT_{1F} (60%) receptor [79]. These three receptors are situated such that they can modulate the release of glutamate from CNS terminals of the TG neurons. Glutamate has been shown to mediate trigeminovascular nociceptive transmission through N-methyl-D-aspartate (NMDA) and non-NMDA receptors in the TNC [49], and it is an important neurotransmitter in the development and maintenance of central sensitization. Thus, inhibition of glutamate release in the TNC via 5-HT receptor activation may not only attenuate early stages of migraine headache, but may reduce glutamate effects during the later stages where central sensitization and cutaneous allodynia are believed to occur [31, 33–36]. Double-labeling studies performed in the vestibular nuclei of rats revealed that neurons positive for glutamate [80] or CGRP [81] also expressed label for the 5-HT_{1F} receptor, providing additional evidence that activation of this receptor may inhibit the release of glutamate and CGRP in CNS sites.

Imaging studies have implicated several brain regions in migraine, including the thalamus PAG, and the TNC [24, 82]. Expression of 5-HT_{1F} receptors in the thalamus represents another site where a 5-HT_{1F} agonist might contribute to an anti-migraine effect, possibly in part by preventing or reversing central sensitization; however, this has not been confirmed or refuted by any studies. The midbrain PAG is a region that is intricately linked to analgesia, and also may contribute to migraine [83]. Early clinical studies with electrical stimulation of the PAG produced relief of otherwise intractable pain [84]. Unexpectedly, some patients also developed migraine-like headaches after implantation of the electrodes into the PAG [84]. fMRI studies have shown activation of the PAG during a migraine attack. The microinjection into the PAG of naratriptan, which has equivalent affinity for the 5-HT_{1B}, 5-HT_{1D}, and 5-HT_{1F} receptors [52], produced a seemingly selective inhibition of TNC neurons to meningeal stimuli, but not cutaneous facial stimuli [85]. In that study, the evoked responses of TNC neurons were recorded in response to stimuli applied to the dura, facial skin, and cornea. Microinjection of naratriptan into the PAG inhibited nociceptive inputs in the TNC from dural, but not facial or corneal nociceptive stimuli [85]. Although this study focused on the potential role of 5-HT_{1B/1D} receptors in modulating TNC neurons from the PAG, the potential role of 5-HT_{1F} receptors was not excluded.

Migraine involves activation of PNS nerve endings that send signals from the dural meninges covering the brain to the TG; then the signal is propagated to CNS brain stem nuclei such as the trigeminal nucleus caudalis, followed by signaling to the hypothalamus and thalamus and ascending signals to the cortex (Fig. 1a,b,c) [72–76, 82]. When serotonin binds to the 5-HT_{1F} receptor, it inhibits neuropeptide and neurotransmitter release, inhibiting transmitter local activity and downstream neuronal signaling (Fig. 2b, Fig. 1d) [74, 75, 81, 86].

Lasmiditan mechanism of action

5-HT_{1F} agonists similar to Lasmiditan

Compounds LY344864 and LY334370 are selective ligands for the 5-HT_{1F} receptor that were not commercialized as clinical therapies but are useful pharmacologic tools for the characterization of this receptor. LY344864 binds to the cloned human 5-HT_{1F} receptor with a K_i of 6 nM, and with poor affinity (≥ 500 nM) for other serotonergic receptors [87]. LY344864 inhibited forskolin-induced accumulation of cAMP and inhibited plasma extravasation in rats [87]. Whereas LY344864 did not produce any contractions of rabbit saphenous vein up to a concentration of 10^{-4} M, the triptans: sumatriptan, zolmitriptan, rizatriptan, and naratriptan, all produced contractions, suggesting vasoconstrictive activity [9]. CNS penetration of a single

peripheral dose of LY344864 (1 mg/kg, IV) was indicated by persistent cortical levels detected over 8 h [87]. Systemically administered LY344864 inhibited *c-fos* expression in the TNC of rats in response to intracisternal administration of capsaicin [88]. Increased expression of the immediate early gene *c-fos* or of its protein product Fos is a reliable biomarker of nociceptive stimulation, while inhibition of *c-fos* expression and TNC neuronal activity are suggestive of a CNS-mediated effect [52].

LY334370 is also a highly selective agonist for the 5-HT_{1F} receptor, with a K_D of 0.446 nM for the human 5-HT_{1F} receptor [89]. There was a statistically significant correlation between [³⁵S] GTP binding of LY334370 in cell homogenates expressing the 5-HT_{1F} receptor and forskolin-stimulated cAMP formation as well as with plasma protein extravasation caused by electrical stimulation of meninges [89, 90]. In addition, LY334370 inhibited Fos expression in the TNC and reduced neuronal firing rates of TNC neurons in response to dural stimuli, suggesting a potential CNS-mediated effect [52, 88]. LY334370 did not induce contractions in the rabbit saphenous vein either alone or in the presence of a baseline vascular tone induced by PGF_{2α} [52], and LY334370 did not constrict human meningeal and cerebral arteries in vitro [91]. This compound was found to be effective and well tolerated for the acute treatment of episodic migraine [52, 91]. Adverse events (AE) included asthenia, dizziness, and somnolence, which suggest that LY334370 acts at CNS sites. It was not commercially developed, however, as preclinical toxicology results suggested potential off-target liver toxicity [52].

Lasmiditan

Lasmiditan (formerly COL-144, LY573144) is a first-in-class “ditan” compound that has a pyridinoyl-piperidine scaffold and differs from LY334370 and triptans by the absence of an indole core [92]. Lasmiditan is a selective 5-HT_{1F} agonist approved in the US for the acute treatment of migraine with or without aura in adults [93]. It is highly selective for the human 5-HT_{1F} receptor, with a K_i of 2.21 nM, compared to values of 1053 nM, 1043 nM, and 1357 nM for the 5-HT_{1A/B/D} receptors, respectively [92]. Lasmiditan has greater than 440 times more potent binding affinity for 5-HT_{1F} versus 5-HT_{1B} and 5-HT_{1D} receptors. Lasmiditan showed no discernable agonist activity at the 5-HT_{1B/D} receptors as determined by stimulation of [³⁵S]-GTPγS binding, but had nanomolar efficacy at the 5-HT_{1F} receptor in this assay [92]. In a recent study where second-messenger activity of receptor activation was analyzed, it was found that almotriptan, avitriptan, eletriptan, frovatriptan, naratriptan, sumatriptan, and zolmitriptan showed varying magnitudes of agonist activity at the 5-HT_{1B/D} as well

as the 5-HT_{1F} receptors, whereas lasmiditan only showed agonist activity at the 5-HT_{1F} receptor [94].

In studies performed with several structurally diverse serotonergic agonists, there was a significant correlation between contractile potency in either the rabbit or canine saphenous vein with potency for contraction of human cerebral arteries, suggesting that the saphenous vein assay may be predictive of human vasoconstrictive activity [95]. Lasmiditan has no discernable vasoconstrictive effects at concentrations up to 100 μM in the rabbit saphenous ring assay, which is a reliable predictor of human coronary artery vasoconstrictor liability [92]. More recently, the activity of lasmiditan in isolated human coronary arteries, internal mammary arteries, and middle meningeal arteries was compared to that of sumatriptan [94]. Lasmiditan did not produce any significant contractions at all doses tested in these isolated human arteries, whereas dose-dependent contractions occurred with sumatriptan. In in vivo studies in anesthetized beagles, lasmiditan did not decrease carotid artery diameter or blood flow at clinically relevant doses [94]. Activation of second messenger for the 5-HT_{1B} receptor, but not for the 5-HT_{1D} or the 5-HT_{1F} receptors, correlated significantly with contractile potency [94]. These in vitro human isolated blood vessel and in vivo anesthetized canine results suggest that, unlike triptans, lasmiditan is not vasoconstrictive at active doses.

In one study, dilation of the middle meningeal artery in response to endogenously released CGRP via either capsaicin injection or periarterial electrical stimulation, as well as to exogenously administered CGRP, was measured in anesthetized rats [96]. Lasmiditan (0.3–10 mg/kg) or sumatriptan (3–10 mg/kg) produced significant (*p* < 0.05) dose-dependent inhibition of endogenous but not exogenous CGRP, indicating that lasmiditan can inhibit dural CGRP release but is not a CGRP receptor antagonist [96]. Unlike sumatriptan, lasmiditan did not produce any significant blood pressure changes [96]. In other studies, lasmiditan blocked electrical stimulation of trigeminal afferent neurons innervating the dura activated TNC neurons [76]. Lasmiditan that was orally administered 1 h prior to electrical stimulation of the TG of anesthetized rats inhibited dural plasma protein extravasation in a dose-dependent manner [92]. In addition, orally-administered doses of lasmiditan blocked the expression of *c-fos* in the TNC in response to electrical stimulation of the TG [92]. Together with the absence of vasoconstrictive effect, these preclinical results showed that lasmiditan has high potency and efficacy at the 5-HT_{1F} receptor, but not the 5-HT_{1B} or 5-HT_{1D} receptors.

The induced expression of Fos in the TNC is a marker of nociceptive activation of the second-order neurons, and is mediated largely through glutamate released from

trigeminal nerve terminals in the TNC [97]. Moreover, glutamate release drives central sensitization in the TNC [98]. Consequently, lasmiditan may alleviate migraine at least in part by activation of 5-HT_{1F} receptors present on glutamatergic trigeminal nerve terminals in the TNC [79].

RCTs have demonstrated that lasmiditan is efficacious, safe, and generally well tolerated for the acute treatment of migraine. In a proof-of-concept, multi-center trial (NCT00384774), intravenous (IV) doses of 10 mg to 40 mg of lasmiditan resulted in pain-free rates at 2 h ranging from 20.8% (10 mg) to 37.5% (30 mg), compared to a 19% rate for placebo [99]. The response rates, based on patients reporting reduction in headache severity from moderate or severe at baseline to mild or no headache, were 54% to 75% at 2 h, which were significantly ($p = 0.013$) superior to placebo [99]. AEs included dizziness, paresthesia, and sensations of heaviness, suggestive of CNS-mediated effects [99].

In another phase II RCT (NCT00883051), oral doses of 50, 100, 200, or 400 mg of lasmiditan likewise proved significantly superior to placebo in reducing migraine headache severity from moderate or severe at baseline to mild or no headache at 2 h [12]. A significantly greater proportion of patients was pain-free at 2 h after 200 mg (19%, $p = 0.032$) and 400 mg (28%, $p = 0.0007$) of lasmiditan [12].

SAMURAI (NCT02439320), a phase III RCT, evaluated the efficacy of oral doses of lasmiditan (100 and 200 mg) [100] and demonstrated that a significantly ($p < 0.001$) greater proportion of patients was headache-free at 2 h with 100 mg (28.2%) and 200 mg (32.2%) mg of lasmiditan, compared to placebo (15.3%) [100]. Similar results were obtained with the phase III RCT SPARTAN (NCT02605174), but this study did not exclude patients who had coronary artery disease, cardiac arrhythmias, or uncontrolled hypertension [13]. The presence of cardiovascular risk factors in patients receiving lasmiditan did not result in either decreased efficacy of lasmiditan or in an increase in frequency of likely cardiovascular treatment-emergent AEs [101]. Overall, the most commonly reported AEs in both phase III studies and in the phase II study with the orally-administered lasmiditan were dizziness, paresthesia, somnolence, fatigue, nausea, lethargy (including a sensation of heaviness), and vertigo [102].

The AEs of somnolence and fatigue suggest that lasmiditan produces CNS-mediated effects [102, 103]. AEs such as dizziness and vertigo associated with lasmiditan could be generated through PNS-mediated effects since vestibular organelles (e.g., cochlear inner hair cells and vestibular hair cells) and the vestibular ganglion are extensively positive for 5-HT_{1F} receptor immunoreactivity [63]. PNS vestibular serotonergic activity is likely

associated with comorbidity of migraine and balance disorders, vestibular migraine, and migraine-related tinnitus or phonophobia [63, 65, 104, 105]. This concept is supported by the fact that IV serotonin infusions can elicit plasma extravasation in specific inner ear tissues, vestibular nerve, and associated ganglia [106].

Comparison of Ditans with Triptans

Although triptans are considered the gold standard for the treatment of acute migraine, they still present some drawbacks [74, 107]. Their mechanism is mediated by the 5-HT_{1B} receptor and includes vasoconstriction, so they are contraindicated in patients who have cardiovascular or cerebrovascular disease [75]. Moreover, triptans are ineffective in approximately 40% of migraine attacks and provide insufficient efficacy for about one-quarter of patients [74, 107].

Ditans provide a different mechanism of action compared to triptans in the treatment of a migraine attack. A post-hoc analysis of pooled data from the phase III SAMURAI and SPARTAN RCTs was undertaken to determine whether the efficacy of lasmiditan differed because of prior triptan therapy response [108]. Regardless of prior response to triptan use, patients taking lasmiditan had greater efficacy than those taking placebo. This benefit did not vary significantly between patients with a good response and those with an insufficient response (i.e., insufficient efficacy) to prior triptan use. Treatment-emergent AEs were similar across subpopulations regardless of prior triptan experience or response to triptan use [108].

It is unclear if there is a CNS component to the efficacy of triptans against migraine. Sumatriptan is poorly lipophilic and does not cross the BBB to any appreciable extent. CNS effects may contribute to the efficacy of second-generation triptans (e.g. zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, frovatriptan, donitriptan, and avitriptan) [74]. However, literature values for triptans' distribution coefficients, indicative of lipophilicity, vary considerably. Although these triptans are somewhat more lipophilic than sumatriptan, their values do not differ much, and their ability to penetrate the CNS is poor when compared to CNS-active drugs [74, 109, 110].

BBB efflux transporters such as P-glycoprotein (P-gp) can substantially reduce the CNS concentration of triptans [74, 111]. For example, the brain concentration of eletriptan, the most lipophilic among the triptans, was 40 times greater in knock-out mice that did not express the *Mdr1a* gene, which codes for P-gp, when compared to the wild type; thus, eletriptan is considered to be a "good" substrate for this efflux transporter [74, 111]. The brain:blood ratios of naratriptan and rizatriptan were significantly reduced in mice expressing *Mdr1a*,

suggesting that they also may be efflux transporter substrates [111]. Other studies have concluded that there is no significant correlation between lipophilicity coefficients of triptans and their efficacy in relieving migraine [110]. These data suggest there may not be a major CNS mechanism associated with triptans' therapeutic effect in migraine. Of note, neither the small molecule CGRP antagonists, nor the large monoclonal antibodies [57] appear to have any clinically appreciable ability to cross the BBB; thus, they may also not have a CNS component to their efficacy.

Lasmiditan, on the other hand, is highly lipophilic and capable of penetrating the BBB (Fig. 1e, Supplemental Video) [10, 92, 112]. Studies with epithelial cell lines revealed that lasmiditan had significant permeability across cell membranes and thus would readily cross the BBB [10]. In a preclinical study with mice receiving an IV injection of 1 mg/kg of lasmiditan, the brain/plasma ratio 2 h after injection was 1.57, indicating a high degree of CNS penetration for lasmiditan [10]. Lasmiditan crossed the BBB of rats as evidenced by brain-to-plasma ratios after IV and oral dosing, with CNS lasmiditan concentration of 0.7 to 1.2 $\mu\text{g Eq/g}$ vs. 0.9 $\mu\text{g Eq/g}$ in the blood/plasma [10]. These preclinical in vitro and in vivo animal distribution observations indicated that lasmiditan can cross the BBB and potentially alleviate migraine through CNS mechanisms, possibly in combination with PNS effects (Fig. 1e,f, Supplemental Video) [10, 92, 112]. This is consistent with the fact that the most common AEs associated with lasmiditan are CNS-mediated effects [102, 103]. However, the fact that lasmiditan has some central effects does not prove that its efficacy against migraine is mediated in the CNS. Preclinical and ex vivo evidence suggested that lasmiditan may inhibit PNS and CNS pain pathways, including the trigeminal nerve. Inhibition is likely via decreased release of neuropeptides and neurotransmitters such as CGRP and glutamate, thereby attenuating local activity and neuronal firing (Fig. 1e,f) [75].

A role for mitochondria?

It has been suggested that neuronal excitability and susceptibility to migraine could be due in part to mitochondrial dysfunction [113]. Studies using phosphorus magnetic resonance spectroscopy showed impaired brain oxidative energy metabolism related to mitochondrial dysfunction in patients with migraine between and during attacks [114, 115]. Conversely, a double-blind RCT reported that a proprietary blend of Mg^{++} , coenzyme Q10 (designed to enhance mitochondrial function), and riboflavin significantly reduced the burden of migraine [116]. Epigenetic regulation of mitochondrial DNA could represent a factor in the migraine pathogenesis [113].

Mitochondrial biogenesis helps maintain mitochondrial homeostasis, and the induction of mitochondrial biogenesis has been shown to normalize mitochondrial dysfunction [117]. In a series of in vitro and in vivo studies, it was found that activation of 5-HT_{1F} receptors with the selective agonists LY334370 and LY344864 increased carbonyl cyanide-p-trifluoromethoxyphenylhydrazone-uncoupled oxygen consumption in renal proximal tubule cells and increased the expression of mitochondrial proteins [117]. Small interfering RNA knockdown of the 5-HT_{1F} receptor blocked mitochondrial biogenesis induced by LY334370 and LY344864. Moreover, LY344864 enhanced the recovery of renal function in an animal model of acute kidney injury by increasing mitochondrial biogenesis [117]. In other studies, LY344864 enhanced mitochondrial homeostasis in control and in 6-hydroxydopamine lesioned mice, and increased locomotor activity in the lesioned mice [118]. These data suggest mitochondrial dysfunction could have a role in migraine pathophysiology, and that perhaps 5-HT_{1F} receptor activity could help offset this dysfunction.

Treatment of human glomerular endothelial cells and mouse glomerular endothelial cells with 5-HT_{1F} receptor agonists LY344864 or lasmiditan (0–500 nM) induced mitochondrial biogenesis as evidenced by maximal mitochondrial respiration, increased nuclear- and mitochondrial-encoded proteins, and increased mitochondrial number [119]. Collectively these studies showed that agonists at the 5-HT_{1F} receptor can enhance mitochondrial activity. The role mitochondrial dysfunction may play in migraine pathophysiology requires further investigation. Whether or not restoration of normal mitochondrial function through 5-HT_{1F} receptor activity plays a role in treatment for migraine also needs additional research.

Conclusion

The discovery that activation of 5-HT_{1F} receptors could provide benefits without the cardiovascular risks associated with triptans was an important advancement in the research on therapeutics for the treatment of migraine. Evidence suggested lasmiditan PNS activation of the 5-HT_{1F} receptor can inhibit the release of CGRP from trigeminal afferent nerves in the PNS [63], thus mimicking the behavior of triptans, CGRP antagonists, and CGRP antibodies. Lasmiditan appears to cross the BBB and may also act upon 5-HT_{1F} receptors found in CNS sites where the receptor potentially can modulate central sensitization of the TNC and thalamus. Receptor activation may also activate elements of descending pain modulation. Lasmiditan activation of the 5-HT_{1F} receptor does not mediate vasoconstriction, thus eliminating a risk associated with triptans. Evidence is emerging that agonists at the 5-HT_{1F} receptor may also stimulate

mitochondrial biogenesis, which potentially could help mitigate migraine, although more research is needed.

Lasmiditan is a highly selective, lipophilic, high-affinity 5-HT_{1F} agonist. While the precise mechanism of action is unknown, preclinical in vitro and in vivo animal data as well as ex vivo human evidence suggested that lasmiditan exerts its therapeutic effects through agonist action at PNS and CNS 5-HT_{1F} receptors. This profile suggested that lasmiditan may act through a mechanism not fully engaged by current migraine therapies. Lasmiditan may be beneficial for patients who have insufficient efficacy, a contraindication, or an intolerability to other current migraine therapeutics.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s10194-020-01132-3>.

Additional file 1.

Acknowledgements

Colleen Dumont of Evidera provided editorial assistance. We thank Alexandra Wallem, University of Kentucky PharmD Candidate 2020, for her help with the literature searches. Eli Lilly and Company contracted Evidera for medical writing and editorial services.

Authors' contributions

All authors contributed to writing and/or to the critical revision of the manuscript. All authors approved the final draft of the manuscript.

Funding

This work is sponsored by Eli Lilly and Company.

Availability of data and materials

The literature and datasets used for the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

David B. Clemow, Kirk W. Johnson, Helen M. Hochstetler, and Ann M. Hake are employed by and are stockholders of Eli Lilly and Company. Michael H. Ossipov is employed by Evidera and owns some Lilly stock. Andrew M. Blumenfeld has received fees for consulting and promotional speaking from Eli Lilly and Company.

Author details

¹Eli Lilly and Company, Indianapolis, IN, USA. ²Evidera, Morrisville, NC, USA. ³Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA. ⁴The Headache Center of Southern California, San Diego, CA, USA.

Received: 11 March 2020 Accepted: 25 May 2020

Published online: 10 June 2020

References

- Villalón CM, VanDenBrink AM (2017) The role of 5-Hydroxytryptamine in the pathophysiology of migraine and its relevance to the Design of Novel Treatments. *Mini Rev Med Chem* 17(11):928–938
- Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. *Nat Rev Neurol* 6(10):573–582
- Edvinsson L, Ho TW (2010) CGRP receptor antagonism and migraine. *Neurotherapeutics* 7(2):164–175
- Aggarwal M, Puri V, Puri S (2012) Serotonin and CGRP in migraine. *Ann Neurosci* 19(2):88–94
- Ahn AH, Basbaum AI (2005) Where do triptans act in the treatment of migraine? *Pain*. 115(1–2):1–4
- Xavier AS, Lakshmanan M, Gunaseelan V (2017) The journey of the non-vascular relief for migraine: from 'Triptans' to 'Ditans'. *Curr Clin Pharmacol* 12(1):36–40
- Holland PR, Sureda-Gibert P, Vila-Pueyo M (2020) Rapid uptake of sumatriptan into the brain: an ongoing question of blood-brain barrier permeability. *Cephalalgia*. 40(4):327–329
- Muzzi M, Zecchi R, Ranieri G, Urru M, Tofani L, De Cesaris F et al (2020) Ultra-rapid brain uptake of subcutaneous sumatriptan in the rat: implication for cluster headache treatment. *Cephalalgia*. 40(4):330–336
- Cohen ML, Schenk K (1999) 5-Hydroxytryptamine (1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin (1F) receptor agonist in rabbit saphenous vein. *J Pharmacol Exp Ther* 290(3):935–939
- Kovalchin J, Ghiglieri A, Zanelli E, Ings R, Mathers T (2016) Lasmiditan acts specifically on the 5-HT_{1F} receptor in the central nervous system. *Cephalalgia* 36(Supplement 1):103.
- Goadsby PJ, Holland PR (2018) Migraine therapy: current approaches and new horizons. *Neurotherapeutics*. 15(2):271–273
- Farkkila M, Diener HC, Geraud G, Lainez M, Schoenen J, Harner N et al (2012) Efficacy and tolerability of lasmiditan, an oral 5-HT (1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. *Lancet Neurol* 11(5):405–413
- Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK et al. (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. *Brain* 142(7):1894–904.
- Wietecha LA, Kuca B, AsafuAdjei J, Aurora SK, Daniele MI (2018) Phase 3 studies (SAMURAL, SPARTAN) of lasmiditan compared to placebo for acute treatment of migraine. *Postgraduate Med* 130(Supplement 1):53–54
- Wietecha LA, Kuca B, Case MG, Selzler KJ, Aurora SK (2018) Phase-3 study (SPARTAN) of Lasmiditan compared to placebo for acute treatment of migraine. *Eur J Neurol* 25(Supplement 2):79
- May A, Burstein R (2019) Hypothalamic regulation of headache and migraine. *Cephalalgia*. 333102419867280
- Tajti J, Szok D, Majlath Z, Tuka B, Csati A, Vecsei L (2015) Migraine and neuropeptides. *Neuropeptides*. 52:19–30
- Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. *Physiol Rev* 94(4):1099–1142
- Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT (1997) Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. *Cephalalgia*. 17(7):785–790
- Goldstein DJ, Offen WW, Klein EG, Phebus LA, Hipskind P, Johnson KW et al (2001) Lanepitant, an NK-1 antagonist, in migraine prevention. *Cephalalgia*. 21(2):102–106
- Hoffmann J, Miller S, Martins-Oliveira M, Akerman S, Suprinsinchai W, Sun H, et al (2020) PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache? *Pain*. <https://doi.org/10.1097/j.pain.0000000000001858>.
- Aurora SK, Brin MF (2017) Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. *Headache*. 57(1):109–125
- De Felice M, Ossipov MH (2016) Cortical and subcortical modulation of pain. *Pain Manag* 6(2):111–120
- Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S (2017) Pathophysiology of migraine: a disorder of sensory processing. *Physiol Rev* 97(2):553–622
- Iyengar S, Johnson KW, Ossipov MH, Aurora SK (2019) CGRP and the trigeminal system in migraine. *Headache*. 59(5):659–681
- Ossipov MH (2012) The perception and endogenous modulation of pain. *Scientifica (Cairo)* 2012:561761
- Ossipov MH, Morimura K, Porreca F (2014) Descending pain modulation and chronification of pain. *Curr Opin Support Palliat Care* 8(2):143–151
- Akerman S, Holland PR, Goadsby PJ (2011) Diencephalic and brainstem mechanisms in migraine. *Nat Rev Neurosci* 12(10):570–584
- Goadsby PJ (2012) Pathophysiology of migraine. *Ann Indian Acad Neurol* 15(Suppl 1):S15–S22

30. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine—current understanding and treatment. *N Engl J Med* 346(4):257–270
31. Burstein R, Jakubowski M, Garcia-Nicas E, Kainz V, Bajwa Z, Hargreaves R et al (2010) Thalamic sensitization transforms localized pain into widespread allodynia. *Ann Neurol* 68(1):81–91
32. Olesen J, Burstein R, Ashina M, Tfelt-Hansen P (2009) Origin of pain in migraine: evidence for peripheral sensitisation. *Lancet Neurol* 8(7):679–690
33. Burstein R, Collins B, Jakubowski M (2004) Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. *Ann Neurol* 55(1):19–26
34. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML et al (2008) Cutaneous allodynia in the migraine population. *Ann Neurol* 63(2):148–158
35. Burstein R, Jakubowski M (2004) Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. *Ann Neurol* 55(1):27–36
36. Malick A, Burstein R (2000) Peripheral and central sensitization during migraine. *Funct Neurol* 15(Suppl 3):28–35
37. Nosedà R, Jakubowski M, Kainz V, Borsook D, Burstein R (2011) Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. *J Neurosci* 31(40):14204–14217
38. Borsook D, Burstein R, Becerra L (2004) Functional imaging of the human trigeminal system: opportunities for new insights into pain processing in health and disease. *J Neurobiol* 61(1):107–125
39. Viana M, Sances G, Ghiotto N, Guaschino E, Allena M, Nappi G et al (2016) Variability of the characteristics of a migraine attack within patients. *Cephalalgia*. 36(9):825–830
40. Rua R, McGavern DB (2018) Advances in meningeal immunity. *Trends Mol Med* 24(6):542–559
41. Hougaard A, Amin FM, Christensen CE, Younis S, Wolfram F, Cramer SP et al (2017) Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. *Brain*. 140(6):1633–1642
42. Schankin CJ, Maniyar FH, Seo Y, Kori S, Eller M, Chou DE et al (2016) Lactacystin lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. *Brain*. 139(Pt 7):1994–2001
43. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP (2008) Neuropeptides activate human mast cell degranulation and chemokine production. *Immunology*. 123(3):398–410
44. Sutherland HG, Griffiths LR (2017) Genetics of migraine: insights into the molecular basis of migraine disorders. *Headache*. 57(4):537–569
45. Schulte LH, Allers A, May A (2017) Hypothalamus as a mediator of chronic migraine: evidence from high-resolution fMRI. *Neurology*. 88(21):2011–2016
46. Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ (2014) Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. *Brain*. 137(Pt 1):232–241
47. Schulte LH, May A (2016) The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. *Brain*. 139(Pt 7):1987–1993
48. May A (2017) Understanding migraine as a cycling brain syndrome: reviewing the evidence from functional imaging. *Neuro Sci* 38(Suppl 1): 125–130
49. Storer RJ, Goadsby PJ (1999) Trigemino-vascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. *Neuroscience*. 90(4):1371–1376
50. Storer RJ, Goadsby PJ (2011) 5-HT_{1F} agonists inhibit nociceptive transmission at the trigeminocervical complex. *Cephalalgia*. 31:9–10
51. Tso AR, Goadsby PJ (2014) New Targets for Migraine Therapy. *Curr Treat Options Neurol* 16(11):318.
52. Ramadan NM, Skjarevski V, Phebus LA, Johnson KW (2003) 5-HT_{1F} receptor agonists in acute migraine treatment: a hypothesis. *Cephalalgia*. 23(8):776–785
53. Scott LJ (2020) Ubrogepant: first approval. *Drugs*. 80(3):323–328
54. Biohaven Pharmaceuticals L. Rimegepant: highlights of prescribing information. New Haven, CT2020
55. Hostetler ED, Joshi AD, Sanabria-Bohorquez S, Fan H, Zeng Z, Purcell M et al (2013) In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. *J Pharmacol Exp Ther* 347(2):478–486
56. Neuwelt EA (2004) Mechanisms of disease: the blood-brain barrier. *Neurosurgery*. 54(1):131–140 discussion 41–2
57. Johnson KW, Morin SM, Wroblewski VJ, Johnson MP (2019) Peripheral and central nervous system distribution of the CGRP neutralizing antibody [I(25) I] galcanezumab in male rats. *Cephalalgia*. 39(10):1241–1248
58. Felgenhauer K (1974) Protein size and cerebrospinal fluid composition. *Klin Wochenschr* 52(24):1158–1164
59. Iyengar S, Ossipov MH, Johnson KW (2017) The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. *Pain*. 158(4):543–559
60. Adham N, Kao HT, Schecter LE, Bard J, Olsen M, Urquhart D et al (1993) Cloning of another human serotonin receptor (5-HT_{1F}): a fifth 5-HT₁ receptor subtype coupled to the inhibition of adenylate cyclase. *Proc Natl Acad Sci U S A* 90(2):408–412
61. Bouchelet I, Cohen Z, Case B, Seguela P, Hamel E (1996) Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. *Mol Pharmacol* 50(2): 219–223
62. Johnson KW, Schaus JM, Durkin MM, Audia JE, Kaldor SW, Flaugh ME et al (1997) 5-HT_{1F} receptor agonists inhibit neurogenic dural inflammation in Guinea pigs. *Neuroreport*. 8(9–10):2237–2240
63. Usman HO, Balaban CD (2016) Distribution of 5-HT_{1F} receptors in monkey vestibular and trigeminal ganglion cells. *Front Neurol* 7:173
64. Amrutkar DV, Ploug KB, Hay-Schmidt A, Porreca F, Olesen J, Jansen-Olesen I (2012) mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. *Pain*. 153(4):830–838
65. Bhalla P, Sharma HS, Wurch T, Pauwels PJ, Saxena PR (2002) Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-HT_{1F} receptor. *Eur J Pharmacol* 436(1–2):23–33
66. Cohen Z, Bouchelet I, Olivier A, Villemure JG, Ball R, Stanimirovic DB et al (1999) Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization. *J Cereb Blood Flow Metab* 19(8):908–917
67. Bruinvels AT, Landwehrmeyer B, Gustafson EL, Durkin MM, Mengod G, Branchek TA et al (1994) Localization of 5-HT_{1B}, 5-HT_{1D} alpha, 5-HT_{1E} and 5-HT_{1F} receptor messenger RNA in rodent and primate brain. *Neuropharmacology*. 33(3–4):367–386
68. Castro ME, Pascual J, Romon T, del Arco C, del Olmo E, Pazos A (1997) Differential distribution of [³H] sumatriptan binding sites (5-HT_{1B}, 5-HT_{1D} and 5-HT_{1F} receptors) in human brain: focus on brainstem and spinal cord. *Neuropharmacology*. 36(4–5):535–542
69. Waeber C, Moskowitz MA (1995) Autoradiographic visualisation of [³H]5-carboxamidotryptamine binding sites in the Guinea pig and rat brain. *Eur J Pharmacol* 283(1–3):31–46
70. Waeber C, Moskowitz MA (1995) [³H] sumatriptan labels both 5-HT_{1D} and 5-HT_{1F} receptor binding sites in the Guinea pig brain: an autoradiographic study. *Naunyn Schmiedeberg's Arch Pharmacol* 352(3):263–275
71. Pascual J, Del Arco C, Romon T, Del Olmo E, Pazos A (1996) [³H] Sumatriptan binding sites in human brain: regional-dependent labelling of 5-HT_{1D} and 5-HT_{1F} receptors. *Eur J Pharmacol* 295(2–3):271–274
72. Lucaites VL, Krushinski JH, Schaus JM, Audia JE, Nelson DL (2005) [³H]LY334370, a novel radioligand for the 5-HT_{1F} receptor. II. Autoradiographic localization in rat, Guinea pig, monkey and human brain. *Naunyn Schmiedeberg's Arch Pharmacol* 371(3):178–184
73. Classy JD, Bartsch T, Goadsby PJ (2010) Distribution of 5-HT_{1B}, 5-HT_{1D} and 5-HT_{1F} receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective anti-migraine effect of triptans. *Brain Res* 1361:76–85
74. Rubio-Beltran E, Labastida-Ramirez A, Villalon CM, MaassenVanDenBrink A (2018) Is selective 5-HT_{1F} receptor agonism an entity apart from that of the triptans in antimigraine therapy? *Pharmacol Ther* 186:88–97
75. Vila-Pueyo M (2018) Targeted 5-HT_{1F} therapies for migraine. *Neurotherapeutics*. 15(2):291–303
76. Vila-Pueyo M, Strother L, Page K, Loaraine H, Kovalchin J, Goadsby PJ et al (2016) Lasmiditan inhibits trigeminovascular nociceptive transmission. *Cephalalgia* 36(Supplement 1):152–153
77. Haanes KA, Edvinsson L (2019) Pathophysiological mechanisms in migraine and the identification of new therapeutic targets. *CNS Drugs* 33(6):525–537
78. Pietrobon D, Moskowitz MA (2013) Pathophysiology of migraine. *Annu Rev Physiol* 75:365–391
79. Ma QP (2001) Co-localization of 5-HT_{1B/1D/1F} receptors and glutamate in trigeminal ganglia in rats. *Neuroreport*. 12(8):1589–1591

80. Ahn SK, Khalmuratova R, Jeon SY, Kim JP, Park JJ, Hur DG et al (2009) Colocalization of 5-HT1F receptor and glutamate in neurons of the vestibular nuclei in rats. *Neuroreport*. 20(2):111–115
81. Ahn SK, Khalmuratova R, Jeon SY, Kim JP, Park JJ, Hur DG et al (2009) Colocalization of 5-HT1F receptor and calcitonin gene-related peptide in rat vestibular nuclei. *Neurosci Lett* 465(2):151–156
82. May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. *Nat Rev Neurol* 12(8):455–464
83. Solstrand Dahlberg L, Linnman CN, Lee D, Burstein R, Becerra L, Borsook D (2018) Responsivity of periaqueductal gray connectivity is related to headache frequency in episodic migraine. *Front Neurol* 9:61
84. Raskin NH, Hosobuchi Y, Lamb S (1987) Headache may arise from perturbation of brain. *Headache*. 27(8):416–420
85. Bartsch T, Knight YE, Goadsby PJ (2004) Activation of 5-HT (1B/1D) receptor in the periaqueductal gray inhibits nociception. *Ann Neurol* 56(3):371–381
86. Monteith TS, Goadsby PJ (2011) Acute migraine therapy: new drugs and new approaches. *Curr Treat Options Neurol* 13(1):1–14
87. Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V et al (1997) Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. *Life Sci* 61(21):2117–2126
88. Mitsikostas DD (1999) Sanchez del Rio M, Moskowitz MA, Waeber C. both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. *Eur J Pharmacol* 369(3):271–277
89. Wainscott DB, Krushinski JH Jr, Audia JE, Schaus JM, Zgombick JM, Lucaites VL et al (2005) [3H]LY34370, a novel radioligand for the 5-HT1F receptor. I. in vitro characterization of binding properties. *Naunyn Schmiedeberg's Arch Pharmacol* 371(3):169–177
90. Wainscott DB, Johnson KW, Phebus LA, Schaus JM, Nelson DL (1998) Human 5-HT1F receptor-stimulated [35S] GTPgammaS binding: correlation with inhibition of Guinea pig dural plasma protein extravasation. *Eur J Pharmacol* 352(1):117–124
91. Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW et al (2001) Selective serotonin 1F (5-HT (1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. *Lancet*. 358(9289):1230–1234
92. Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO et al (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. *Cephalalgia*. 30(10):1159–1169
93. Eli Lilly and Company. REYVOW medication guide. 2019
94. Rubio-Beltran E, Labastida-Ramirez A, Haanes KA, van den Bogaerd A, Bogers A, Zanelli E et al (2019) Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan. *Br J Pharmacol* 176(24):4681–4695
95. Cohen ML, Johnson KW, Schenck KW, Phebus LA (1997) Migraine therapy: relationship between serotonergic contractile receptors in canine and rabbit saphenous veins to human cerebral and coronary arteries. *Cephalalgia*. 17(6):631–638
96. Labastida-Ramirez A, Rubio-Beltran E, Haanes KA, Chan KY, Garrelts IM, Johnson KW et al (2020) Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. *Pain*. 161(5):1092–1099
97. Mitsikostas DD, Sanchez del Rio M, Waeber C, Huang Z, Cutrer FM, Moskowitz MA (1999) Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. *Br J Pharmacol* 127(3):623–630
98. Hoffmann J, Charles A (2018) Glutamate and its receptors as therapeutic targets for migraine. *Neurotherapeutics*. 15(2):361–370
99. Ferrari MD, Farkkila M, Reuter U, Pilgrim A, Davis C, Krauss M et al (2010) Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan—a randomised proof-of-concept trial. *Cephalalgia*. 30(10):1170–1178
100. Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB et al (2018) Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. *Neurology*. 91(24):e2222–e2e32
101. Shapiro RE, Hochstetler HM, Denney EB, Khanna R, Doty EG, Berg PH et al (2019) Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. *J Headache Pain*. 20(1):90
102. Kudrow D, Kregge J, Hundemer HP, Berg PH, Khanna R, Ossipov MH, et al. Issues impacting adverse event frequency and severity: Differences between randomized phase 2 and phase 3 clinical trials for lasmiditan. *Headache*. 2019;in press
103. Kregge JH, Rizzoli PB, Liffick E, Doty EG, Dowsett SA, Wang J et al (2019) Safety findings from phase 3 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN. *Cephalalgia*. 39(8):957–966
104. Furman JM, Marcus DA, Balaban CD (2011) Rizatriptan reduces vestibular-induced motion sickness in migraineurs. *J Headache Pain*. 12(1):81–88
105. Furman JM, Marcus DA, Balaban CD (2013) Vestibular migraine: clinical aspects and pathophysiology. *Lancet Neurol* 12(7):706–715
106. Koo JW, Balaban CD (2006) Serotonin-induced plasma extravasation in the murine inner ear: possible mechanism of migraine-associated inner ear dysfunction. *Cephalalgia*. 26(11):1310–1319
107. Diener HC, Limmroth V (2001) Advances in pharmacological treatment of migraine. *Expert Opin Investig Drugs* 10(10):1831–1845
108. Kniewel K, Buchanan AS, Lombard L, Baygani S, Raskin J, Kregge JH et al (2019) Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. *Cephalalgia*. 33(10):1989–2000
109. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ et al (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. *J Pharmacol Exp Ther* 303(3):1029–1037
110. Pascual J, Munoz P (2005) Correlation between Lipophilicity and Triptan outcomes. *Headache*. 45:3–6
111. Evans DC, O'Connor D, Lake BG, Evers R, Allen C, Hargreaves R (2003) Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. *Drug Metab Dispos* 31(7):861–869
112. Raffaelli B, Israel H, Neeb L, Reuter U (2017) The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine. *Expert Opin Pharmacother* 18(13):1409–1415
113. Fila M, Pawlowska E, Blasiak J (2019) Mitochondria in migraine pathophysiology - does epigenetics play a role? *Arch Med Sci* 15(4):944–956
114. Lodi R, Lotti S, Cortelli P, Pierangeli G, Cevoli S, Clementi V et al (2001) Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. *Brain Res Bull* 54(4):437–441
115. Sparaco M, Feleppa M, Lipton RB, Rapoport AM, Bigal ME (2006) Mitochondrial dysfunction and migraine: evidence and hypotheses. *Cephalalgia*. 26(4):361–372
116. Gaul C, Diener HC, Danesch U, Migravent SG (2015) Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. *J Headache Pain* 16:516
117. Garrett SM, Whitaker RM, Beeson CC, Schnellmann RG (2014) Agonism of the 5-hydroxytryptamine 1F receptor promotes mitochondrial biogenesis and recovery from acute kidney injury. *J Pharmacol Exp Ther* 350(2):257–264
118. Scholpa NE, Lynn MK, Corum D, Boger HA, Schnellmann RG (2018) 5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease. *Br J Pharmacol* 175(2):348–358
119. Dupre TV, Jenkins DP, Muise-Helmericks RC, Schnellmann RG (2019) The 5-hydroxytryptamine receptor 1F stimulates mitochondrial biogenesis and angiogenesis in endothelial cells. *Biochem Pharmacol* 169:113644

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

